The Global OTC Pharmaceutical Market

2010-2025

Product Code VIS00062
Publication Date July 2010
Publisher Visiongain
Product Type Report
Pages 137
ISBN Number not applicable
Change currency
PDF £1,499.00 €1,805 $2,370 BUY >
Order by fax
Ask a question about this product > Receive product alerts > Call now +44 20 7060 7474

The Global OTC Pharmaceutical Market

2010-2025

Where will opportunities lie in this diverse market with growing demand worldwide?

In 2009, the global over-the-counter (OTC) pharmaceutical market generated revenues of more than $60bn. Our analyses show that total OTC revenues will exceed $70bn by 2015. From 2010 onwards, Rx-to-OTC switching and the continuing importance of emerging healthcare markets will drive sales in this sector. Our forecasts reveal that the OTC pharma market will grow significantly from 2010 onwards. This report explains where future OTC switching and other developments will occur, providing you with the information that you need to understand the current OTC market and its future prospects.

Our new report - The Global OTC Pharmaceutical Market 2010-2025 - explains how this market will develop, and where the opportunities will lie. We show how you can benefit from its developments and potential.

That study examines all the prominent OTC pharmaceutical categories, including:

  • Cough, cold and allergy medications
  • Analgesics
  • Gastrointestinal drugs
  • Dermatological preparations
  • Smoking-cessation aids
  • Others - including contraceptives, anti-obesity treatments, statins and erectile dysfunction treatments.

What types of OTC medications are likely to enter the market from 2010 onwards, and what will their sales potential be like? Where will the main opportunities lie, and what are the drivers and restraints in this market sector? Our study will provide you with up-to-date information that you need to understand current trends and future directions in the market.

Comprehensive analysis of the global OTC pharmaceutical industry and market

The Global OTC Pharmaceutical Market 2010-2025 examines that sector through a comprehensive review of information sources. We harness primary and secondary research. This report provides unique sales forecasts, market share analyses, discussions of Rx-OTC switching developments and analyses of commercial drivers and restraints, including a SWOT analysis. There are over 90 tables and figures included, as well as an expert interview. The result is an extensive market- and industry-centred study, with detailed analyses and informed opinion to benefit your work.

Why you should buy this report?

This report gives you the following benefits in particular:

  • You will assess the current OTC pharmaceutical market
  • You will receive a forecast for the overall OTC pharmaceutical market from 2010 to 2025, with global revenues and supporting discussions
  • You will view revenue forecasts for the leading OTC pharmaceutical categories from 2010 to 2025, with discussions of market potential and competition
  • You will view revenue forecasts for the leading companies in the OTC sector from 2010 to 2015, with discussions and other supporting information
  • You will view revenue forecasts from 2010 to 2025 for leading products in this market, with discussions of market potential and competition
  • You will receive OTC revenue forecasts for leading national markets from 2010 to 2025, with supporting discussions
  • You will analyse the drivers, restraints, competition and opportunities influencing the market for OTC pharmaceuticals from 2010 onwards
  • You will receive coverage of OTC switching from 2010 onwards, highlighting important developments likely to occur
  • You will discover expert views on that industry/market sector, including a full interview transcript.

You can obtain this report today.

Our new report is essential reading for everybody interested in the OTC pharmaceutical industry and market. We predict that total revenues will increase during our forecast period. High costs of prescription drugs combined with strained healthcare budgets and high, rising prevalence of the many conditions treated by OTC medications will drive market growth.

Do you want to harness the opportunities in this market area? You can stay ahead by ordering our report today.

Contents

  • 1. Executive Summary
    • 1.1 OTC Market Review
    • 1.2 Aims, Scope and Format of the Report
    • 1.3 Research and Analysis Methods
  • 2. Introduction to OTC Pharmaceuticals
    • 2.1 OTC Pharmaceuticals
    • 2.2 Main Features of OTC Pharmaceuticals
    • 2.3 OTC Switching
    • 2.4 Manufacture and Distribution of OTC Pharmaceuticals
    • 2.5 Regulation of OTC Pharmaceuticals
      • 2.5.1 United States
      • 2.5.2 Japan
      • 2.5.3 European Union
      • 2.5.4 Other Countries
    • 2.6 Major OTC Pharmaceutical Therapeutic Categories
    • 2.7 Analgesics
      • 2.7.1 Internal Analgesics
      • 2.7.2 External Analgesics
    • 2.8 Cough, Cold, and Allergy Products
      • 2.8.1 Cough and Cold Remedies
      • 2.8.2 Anti-Allergy OTC Products
    • 2.9 Dermatological Products
      • 2.9.1 Minor Cuts and Wounds
      • 2.9.2 Acne
      • 2.9.3 Rashes, Itchy Skin, Dermatitis and Eczema
      • 2.9.4 Cold Sores
      • 2.9.5 Warts
      • 2.9.6 Fungal Skin Infections
      • 2.9.7 Haemorrhoids
      • 2.9.8 Other Dermatological Products
    • 2.10 Gastrointestinal Products
      • 2.10.1 Indigestion and Heartburn
      • 2.10.2 Anti-Diarrhoea OTC Pharmaceuticals
      • 2.10.3 Laxatives
      • 2.10.4 Anti-Emetic OTC Pharmaceuticals
      • 2.10.5 Anti-Obesity OTC Pharmaceuticals
    • 2.11 Smoking Cessation Aids
    • 2.12 Other OTC Pharmaceuticals
    • 2.13 Vitamins, Minerals and Supplements
  • 3. The Global OTC Pharmaceutical Market 2010-2025
    • 3.1 Global OTC Pharmaceutical Market
      • 3.1.1 The Global OTC Market in 2009
      • 3.1.2 Global OTC Pharmaceutical Market Forecast, 2010-2025
      • 3.1.3 Significant Increase in Global OTC Revenues by 2025
    • 3.2 OTC Pharmaceutical Categories
      • 3.2.1 Cough, Cold & Allergy Drugs Lead the OTC Market
      • 3.2.2 Leading OTC Drug Categories Sales Forecasts, 2010-2025
    • 3.3 The Leading OTC Pharmaceutical Brands
      • 3.3.1 Tylenol Led the OTC Pharmaceutical Market in 2009
    • 3.4 Tylenol: The Only Blockbuster OTC Brand
      • 3.4.1 Will Tylenol Recalls Affect Sales?
      • 3.4.2 Tylenol Sales Forecast, 2010-2025
    • 3.5 Advil
      • 3.5.1 Advil Sales Forecast, 2010-2025
    • 3.6 Panadol
      • 3.6.1 Panadol Sales Forecast, 2010-2025
    • 3.7 Vicks
      • 3.7.1 Vicks Sales Forecast, 2010-2025
    • 3.8 Nicorette
      • 3.8.1 Nicorette Sales Forecast, 2010-2025
    • 3.9 Nicabate/NicoDerm/Nicorette/NiQuitin
      • 3.9.1 Nicabate/NicoDerm/Nicorette/NiQuitin Sales Forecast, 2010-2025
    • 3.10 Bayer Aspirin
      • 3.10.1 Bayer Aspirin Sales Forecast, 2010-2025
    • 3.11 Prilosec OTC
      • 3.11.1 Prilosec OTC Sales Forecast, 2010-2025
    • 3.12 Leading OTC Pharmaceutical Manufacturers
    • 3.13 Johnson & Johnson
      • 3.13.1 Johnson & Johnson's OTC Pharmaceuticals and Nutritionals
        • Franchise
      • 3.13.2 Johnson & Johnson: The Global OTC Leader in 2009
      • 3.13.3 Johnson & Johnson OTC Pharmaceutical Forecast, 2010-2015
    • 3.14 GlaxoSmithKline
      • 3.14.1 GSK Consumer Healthcare
      • 3.14.2 GSK is Second-Largest Global OTC Pharmaceutical Company: 2009 OTC
        • Sales and Market Shares
      • 3.14.3 GSK OTC Pharmaceutical Forecast, 2010-2015
    • 3.15 Bayer
      • 3.15.1 Bayer Consumer Care
      • 3.15.2 Bayer's OTC Pharmaceuticals: 2009 Sales and Market Shares
      • 3.15.3 Bayer OTC Pharmaceutical Forecast, 2010-2015
    • 3.16 Novartis
      • 3.16.1 Novartis OTC Pharmaceuticals
      • 3.16.2 Novartis' OTC Pharmaceuticals, 2009
      • 3.16.3 Novartis OTC Pharmaceutical Forecast, 2010-2015
      • 3.16.4 Voltaren
      • 3.16.5 Novartis' Nicotine Replacement Business
      • 3.16.6 Otriven, Theraflu, Excedrin and Lamisil: Other Leading Novartis
        • OTC Brands
    • 3.17 Pfizer/Wyeth
      • 3.17.1 Pfizer/Wyeth Consumer Healthcare
      • 3.17.2 Pfizer/Wyeth OTC Pharmaceuticals, 2009
    • 3.18 Sanofi-Aventis
      • 3.18.1 Sanofi-Aventis OTC Division
      • 3.18.2 Sanofi-Aventis OTC Pharmaceuticals, 2009
    • 3.19 Proctor & Gamble
      • 3.19.1 Proctor & Gamble OTC Pharmaceuticals, 2009
    • 3.20 Reckitt Benckiser
      • 3.20.1 Reckitt Benckiser OTC Pharmaceuticals, 2009
    • 3.21 Boehringer Ingelheim
      • 3.21.1 Boehringer Ingelheim Consumer Health Care
      • 3.21.2 Leading Boehringer Ingelheim OTC Pharmaceuticals, 2009
      • 3.21.3 The Dulcolax Franchise
      • 3.21.4 Mucosolvan/Lasolvan and other Leading OTC Products
    • 3.22 Perrigo
      • 3.22.1 Perrigo Consumer Healthcare
      • 3.22.2 Perrigo OTC Pharmaceuticals
  • 4. OTC Switching
    • 4.1 Motivations for OTC Switching
    • 4.2 Recent OTC-Switching Activity
    • 4.3 The Future Prospects for OTC Switching
    • 4.4 Gastrointestinal OTC Switching
      • 4.4.1 H2-Blockers
      • 4.4.2 PPIs Focus of Gastrointestinal OTC Switching
      • 4.4.3 Omeprazole
      • 4.4.4 Lansoprazole
      • 4.4.5 Pantoprazole
      • 4.4.6 Esomeprazole
      • 4.4.7 Rabeprazole
      • 4.4.8 Anti-Obesity OTC Switches
    • 4.5 Cough, Cold and Allergy OTC Switching
      • 4.5.1 First-Generation Antihistamines
      • 4.5.2 Second-Generation Antihistamines
      • 4.5.3 Third-Generation Antihistamines
      • 4.5.4 Fluticasone Propionate
    • 4.6 Analgesic OTC Switching
      • 4.6.1 Triptans
      • 4.6.2 What are the Prospects for OTC Switching of Triptans in the US?
      • 4.6.3 Arthritis Pain
    • 4.7 Dermatological Drugs
    • 4.8 Other OTC-Switching Categories
      • 4.8.1 Oral Contraceptives
      • 4.8.2 Cholesterol-Lowering Drugs
        • 4.8.2.1 OTC Statins
        • 4.8.2.2 Zocor Heart-Pro in the UK
        • 4.8.2.3 The Road to OTC Statins in the US
        • 4.8.2.4 What are the Worldwide Prospects for Statin OTC Switching?
      • 4.8.3 Erectile Dysfunction Drugs
    • 4.9 OTC Switching: a Continuing Trend from 2010-2025
  • 5. Issues Affecting the OTC Pharmaceutical Sector from 2010 Onwards
    • 5.1 SWOT Analysis of the OTC Pharmaceutical Industry and Market
    • 5.2 OTC Switching
    • 5.3 Brand Identity and Private Labels
    • 5.4 Developments in OTC Retail Channels
    • 5.5 Will OTC Move Behind-the-Counter?
    • 5.6 Web 2.0 Advertising Opportunities
    • 5.7 Changing World Demographics
      • 5.7.1 Population Increase and 'Greying' of the World Population
      • 5.7.2 Developing Countries - a Large Market for OTC Products?
    • 5.8 The Worldwide Downturn in Consumer Spending
    • 5.9 Safety Concerns: Misuse and Abuse of OTC Pharmaceuticals
      • 5.9.1 Safety Concerns
      • 5.9.2 OTC Drug Misuse
      • 5.9.3 OTC Drug Abuse
      • 5.9.4 Impact on the OTC Industry
  • 6. Leading National Markets for OTC Medicines 2010-2025
    • 6.1 Leading OTC National Markets in 2009
    • 6.2 Leading OTC National Market Forecasts, 2010-2025
    • 6.3 The US OTC Market, 2010-2025
    • 6.4 The Japanese OTC Market, 2010-2025
    • 6.5 European OTC Markets, 2010-2025
    • 6.6 Emerging OTC Markets, 2010-2025
  • 7. Expert Opinion
    • 7.1 Interview with Joshua P. Cohen, PhD, Senior Research Fellow at the
      • Tufts Center for the Study of Drug Development
      • 7.1.1 Prospects for OTC Statins in the US
      • 7.1.2 Future OTC Switching Categories
      • 7.1.3 Prospects for Behind-the Counter Products in the US
      • 7.1.4 OTC Safety Issues
  • 8. Conclusions
    • 8.1 The Global OTC Market in 2009
      • 8.1.1 Leading OTC Categories
      • 8.1.2 Leading OTC Brands
      • 8.1.3 Leading OTC Pharmaceutical Manufacturers
      • 8.1.4 Leading National OTC Markets
    • 8.2 Global OTC Pharmaceutical Market Forecast, 2010-2025
      • 8.2.1 OTC Growth Drivers
      • 8.2.2 OTC Switching Activity
      • 8.2.3 Emerging OTC Markets
    • 8.3 Future OTC Market Dynamics
  • List of Tables
    • Table 2.1 OTC Internal Analgesic Active Ingredients, 2010
    • Table 2.2 OTC External Analgesic Active Ingredients, 2010
    • Table 2.3 Cough, Cold and Allergy OTC Pharmaceutical Active Ingredients, 2010
    • Table 2.4 Antifungal OTC Pharmaceutical Active Ingredients, 2010
    • Table 2.5 Indigestion and Heartburn OTC Pharmaceutical Active Ingredients, 2010
    • Table 2.6 Anti-Diarrhoea OTC Pharmaceutical Active Ingredients, 2010
    • Table 2.7 OTC Laxative Active Ingredients, 2010
    • Table 2.8 Nicotine Replacement Therapy OTC Formulations, 2010
    • Table 3.1 OTC and Prescription-Only Pharmaceutical Markets, 2009
    • Table 3.2 Global OTC Pharmaceuticals: Sales Forecast, 2010-2017
    • Table 3.3 Global OTC Pharmaceuticals: Sales Forecast, 2018-2025
    • Table 3.4 OTC Category Revenues and Market Shares, 2009
    • Table 3.5 Leading OTC Categories: Sales Forecasts, 2010-2017
    • Table 3.6 Leading OTC Categories: Sales Forecasts, 2018-2025
    • Table 3.7 Leading OTC Brands, 2009
    • Table 3.8 Tylenol Products, 2010
    • Table 3.9 Tylenol Sales Forecast, 2010-2017
    • Table 3.10 Tylenol Sales Forecast, 2018-2025
    • Table 3.11 Advil North American Formulations, 2010
    • Table 3.12 Advil Sales Forecast, 2010-2017
    • Table 3.13 Advil Sales Forecast, 2018-2025
    • Table 3.14 Panadol Formulations, 2010
    • Table 3.15 Panadol Sales Forecast, 2010-2017
    • Table 3.16 Panadol Sales Forecast, 2018-2025
    • Table 3.17 Vicks US Formulations, 2010
    • Table 3.18 Vicks Sales Forecast, 2010-2017
    • Table 3.19 Vicks Sales Forecast, 2018-2025
    • Table 3.20 Nicorette Formulations (Johnson & Johnson), 2010
    • Table 3.21 Nicorette (Johnson & Johnson) Sales Forecast, 2010-2017
    • Table 3.22 Nicorette (Johnson & Johnson) Sales Forecast, 2018-2025
    • Table 3.23 Nicabate/NicoDerm/Nicorette/NiQuitin NRT Brands (GSK), 2010
    • Table 3.24 Nicabate/NicoDerm/Nicorette/NiQuitin (GSK) Sales Forecast, 2010-2017
    • Table 3.25 Nicabate/NicoDerm/Nicorette/NiQuitin (GSK) Sales Forecast, 2018-2025
    • Table 3.26 Bayer Aspirin Formulations, 2009
    • Table 3.27 Bayer Aspirin Sales Forecast, 2010-2017
    • Table 3.28 Bayer Aspirin Sales Forecast, 2018-2025
    • Table 3.29 Prilosec OTC Sales Forecast, 2010-2017
    • Table 3.30 Prilosec OTC Sales Forecast, 2018-2025
    • Table 3.31 Top Ten OTC Pharmaceutical Manufacturers, 2009
    • Table 3.32 Johnson & Johnson OTC Brands, 2009
    • Table 3.33 Johnson & Johnson Total OTC Pharmaceuticals: Sales Forecast, 2010-2015
    • Table 3.34 GSK OTC Brands, 2009
    • Table 3.35 GSK Total OTC Pharmaceuticals: Sales Forecast, 2010-2015
    • Table 3.36 Bayer OTC Brands, 2009
    • Table 3.37 Bayer Total OTC Pharmaceuticals: Sales Forecast, 2010-2015
    • Table 3.38 Novartis OTC Brands, 2009
    • Table 3.39 Novartis Total OTC Pharmaceuticals: Sales Forecast, 2010-2015
    • Table 3.40 Novartis OTC Nicotine Replacement Therapy Products, 2009
    • Table 3.41 Wyeth/Pfizer OTC Brands, 2009
    • Table 3.42 Sanofi-Aventis OTC Brands, 2009
    • Table 3.43 Proctor & Gamble OTC Brands, 2009
    • Table 3.44 Reckitt Benckiser OTC Brands, 2009
    • Table 3.45 Boehringer Ingelheim OTC Brands, 2009
    • Table 4.1 Recent and Future Gastrointestinal OTC Switches
    • Table 4.2 Recent and Future Cough, Cold & Allergy OTC Switches
    • Table 4.3 Recent and Future Analgesic OTC Switches
    • Table 4.4 Recent and Future Dermatological OTC Switches
    • Table 5.1 SWOT Analysis of the OTC Pharmaceutical Sector, 2010
    • Table 5.2 World Population Forecast, 2009-2025
    • Table 5.3 Population Forecasts in Leading OTC Markets, 2009 & 2025
    • Table 6.1 OTC Revenues in Leading OTC National Markets, 2009
    • Table 6.2 Leading OTC National Markets: Sales Forecasts, 2010-2017
    • Table 6.3 Leading OTC National Markets: Sales Forecasts, 2018-2025
  • List of Figures
    • Figure 2.1 The OTC Pharmaceutical Supply Chain, 2010
    • Figure 3.1 OTC and Prescription-Only Pharmaceutical Markets, 2009
    • Figure 3.2 Global OTC Pharmaceuticals: Sales Forecast, 2010-2025
    • Figure 3.3 Leading OTC Drug Categories (Including Vitamins & Minerals): Sales and Market Shares, 2009
    • Figure 3.4 Leading OTC Drug Categories (Excluding Vitamins & Minerals): Sales and Market Shares, 2009
    • Figure 3.5 Leading OTC Drug Categories: Sales Forecasts, 2010-2025
    • Figure 3.6 Leading OTC Drug Categories: Sales and Market Shares, 2015
    • Figure 3.7 Leading OTC Drug Categories: Sales and Market Shares, 2025
    • Figure 3.8 Tylenol Sales Forecast, 2010-2025
    • Figure 3.9 Advil Sales Forecast, 2010-2025
    • Figure 3.10 Panadol Sales Forecast, 2010-2025
    • Figure 3.11 Vicks Sales Forecast, 2010-2025
    • Figure 3.12 Nicorette (Johnson & Johnson) Sales Forecast, 2010-2025
    • Figure 3.13 Nicabate/NicoDerm/Nicorette/NiQuitin (GSK) Sales Forecast, 2010-2025
    • Figure 3.14 Bayer Aspirin Sales Forecast, 2010-2025
    • Figure 3.15 Prilosec OTC Sales Forecast, 2010-2025
    • Figure 3.16 Leading OTC Pharmaceutical Manufacturers: Market Shares, 2009
    • Figure 3.17 Johnson & Johnson Total OTC Pharmaceuticals: Sales Forecast, 2010-2015
    • Figure 3.18 GSK Total OTC Pharmaceuticals: Sales Forecast, 2010-2015
    • Figure 3.19 Bayer Total OTC Pharmaceuticals: Sales Forecast, 2010-2015
    • Figure 3.20 Novartis Total OTC Pharmaceuticals: Sales Forecast, 2010-2015
    • Figure 5.1 World Population Forecast, 2009-2025
    • Figure 5.2 World Population Aged 65 or Over: Forecast, 2009-2025
    • Figure 5.3 Population in Leading OTC Markets: Forecasts, 2009 & 2025
    • Figure 5.4 Population Aged 65 and Over in Leading OTC Markets: Forecasts, 2009 & 2025
    • Figure 6.1 OTC National Market Shares, 2009
    • Figure 6.2 OTC National Market Shares, 2015
    • Figure 6.3 OTC National Market Shares, 2020
    • Figure 6.4 OTC National Market Shares, 2025
  • Companies Listed
    • Alliance Boots
    • Abbott
    • Adams Respiratory Therapeutics [acquired by Reckitt Benckiser, 2008]
    • American Medical Association
    • AmerisourceBergen
    • AstraZeneca
    • AZ Tika [wholly owned by AstraZeneca]
    • Barr [acquired by Teva, 2008]
    • Bayer
    • Bayer Consumer Care
    • Boehringer Ingelheim
    • Bristol-Myers Squibb (BMS)
    • Cardinal Health
    • Celesio
    • Center for Drug Evaluation and Research (CDER)
    • Chattem
    • CNS [acquired by GSK, 2006]
    • Daiichi Sankyo
    • Dexcel Pharma
    • Dr. Reddy's Laboratories
    • Eisai
    • European Medicines Agency (EMA, EMEA)
    • Federal Trade Commission [US]
    • Food and Drug Administration (FDA) [US]
    • Galpharm [acquired by Perrigo, 2008]
    • GlaxoSmithKline (GSK)
    • Johnson & Johnson
    • Kowa Pharmaceuticals
    • Lion Corporation
    • McKesson Corporation
    • McNeil Consumer Healthcare
    • Medicines and Healthcare Products Regulatory Agency (MHRA) [UK]
    • Menarini Group
    • Merck & Co.
    • Ministry of Health, Labour and Welfare (MHLW) [Japan]
    • Mylan Pharmaceuticals
    • Novartis
    • Nycomed
    • Perrigo Company
    • Pfizer
    • Phoenix
    • Proctor & Gamble
    • Public Citizen [US]
    • Ranbaxy Laboratories
    • Ratiopharm
    • Reckitt Benckiser Group
    • Roche Holding
    • Rohto
    • Sagmel [acquired by Bayer, 2008]
    • Sanofi-Aventis
    • Santarus
    • Sato Pharmaceutical
    • Schering-Plough
    • SSL International
    • SSP Co.
    • Sun Pharmaceutical Industries
    • Taisho Pharmaceutical Co.
    • Takeda Pharmaceutical Company
    • Target Corporation
    • Teva Pharmaceutical Industries
    • Therapeutic Goods Administration (TGA) [Australia]
    • Tufts Center for the Study of Drug Development
    • Walmart
    • Wyeth [acquired by Pfizer, 2009]